Pahl et al. studied the cytolytic activity of boosting natural killer to target sarcoma cells, and confirmed that EGFR was expressed by chemotherapy-resistant and chemotherapy-sensitive osteosarcoma cells [99]. Here, EGFR is linked to sarcoma.